BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 24510519)

  • 1. Rise of iPSCs as a cell source for adoptive immunotherapy.
    Minagawa A; Kaneko S
    Hum Cell; 2014 Apr; 27(2):47-50. PubMed ID: 24510519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming away from the exhausted T cell state.
    Karagiannis P; Iriguchi S; Kaneko S
    Semin Immunol; 2016 Feb; 28(1):35-44. PubMed ID: 26589493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
    Nianias A; Themeli M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.
    Iriguchi S; Kaneko S
    Cancer Sci; 2019 Jan; 110(1):16-22. PubMed ID: 30485606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.
    Patel SJ; Yamauchi T; Ito F
    Surg Oncol Clin N Am; 2019 Jul; 28(3):489-504. PubMed ID: 31079802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of memory T cell subsets for adoptive immunotherapy.
    Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
    Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy.
    Kondo T; Imura Y; Chikuma S; Hibino S; Omata-Mise S; Ando M; Akanuma T; Iizuka M; Sakai R; Morita R; Yoshimura A
    Cancer Sci; 2018 Jul; 109(7):2130-2140. PubMed ID: 29790621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pluripotent stem cells as a source for T cell research and clinical application].
    Ueda T; Kaneko S
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(2):101-8. PubMed ID: 26016637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.
    Cichocki F; van der Stegen SJC; Miller JS
    Blood; 2023 Feb; 141(8):846-855. PubMed ID: 36327161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell Genesis: In Vitro Veritas Est?
    Brauer PM; Singh J; Xhiku S; Zúñiga-Pflücker JC
    Trends Immunol; 2016 Dec; 37(12):889-901. PubMed ID: 27789110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.
    Kawai Y; Kawana-Tachikawa A; Kitayama S; Ueda T; Miki S; Watanabe A; Kaneko S
    Mol Ther; 2021 Oct; 29(10):3027-3041. PubMed ID: 34023508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy for cancer: harnessing the T cell response.
    Restifo NP; Dudley ME; Rosenberg SA
    Nat Rev Immunol; 2012 Mar; 12(4):269-81. PubMed ID: 22437939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T-cell therapy of cancer.
    Yee C
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of adoptive T cell cancer therapy.
    June CH
    J Clin Invest; 2007 May; 117(5):1204-12. PubMed ID: 17476350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
    Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
    Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
    Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
    Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of endogenous T cells for adoptive transfer.
    Yee C
    Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-memory cells against cancer: Remembering the enemy.
    Sarkar I; Pati S; Dutta A; Basak U; Sa G
    Cell Immunol; 2019 Apr; 338():27-31. PubMed ID: 30928016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.